ArticleBlood cancer journal2016

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).

D C Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.